We are live on
!
Find out more
FM
Frazier Management Portfolio holdings
AUM
$1.12M
1-Year Est. Return
151.58%
This Fund
S&P 500
This Quarter
Est. Return
+36.28%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$1.14B
AUM Growth
+$257M
(+29%)
Cap. Flow
+$20M
Cap. Flow
% of AUM
1.75%
Top 10 Holdings %
Top 10 Hldgs %
86.4%
Holding
27
New
2
Increased
4
Reduced
3
Closed
1
Avg Time Held
6.7
quarters
Top 10 Avg Time Held
4.7
quarters
Top 20 Avg Time Held
6.2
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vaxcyte
PCVX
|
+$74.3M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$9.85M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
+$5.73M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
+$5.02M |
| 5 |
Adverum Biotechnologies
ADVM
|
+$2.81M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Phathom Pharmaceuticals
PHAT
|
+$56M |
| 2 |
Iovance Biotherapeutics
IOVA
|
+$14.4M |
| 3 |
Tempest Therapeutics
TPST
|
+$7.37M |
| 4 |
ETTX
Entasis Therapeutics Holdings Inc.
ETTX
|
+$1.91M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
BLCM
26
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $781K | 0.07% |
105,144
| – | – |
2018 Q2
8 quarters
|
|
|
27
Tempest Therapeutics
TPST
$11.5M
| – | – |
-7,162
| Closed | -$7.37M | – |
|
Similar funds
ACMV
FRCMI
DB
NAM
AP
ID
CI
DIF
Frazier Management's Q2 2020 Portfolio in Review
As of Q2 2020, Frazier Management held 27 positions worth $1.14B, up 29% from $882M the previous quarter. Its ten largest holdings account for 86% of the portfolio.
Frazier Management's Q2 2020 filing shows 2 new, 4 increased, 3 reduced and 1 closed positions. Its largest new stake was Vaxcyte: 2,309,554 shares worth $73M. The largest sale was Phathom Pharmaceuticals, an estimated $56M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Frazier Management's largest Q2 2020 buy was Vaxcyte: 2,309,554 shares worth $73M.
- Frazier Management added most to Rocket Pharmaceuticals in Q2 2020, an estimated $5.73M increase.
- Frazier Management's biggest Q2 2020 reduction was Phathom Pharmaceuticals, cutting an estimated $56M.
- Frazier Management fully exited Tempest Therapeutics in Q2 2020, selling an estimated $7.37M.
- Frazier Management's ten largest holdings make up 86% of its $1.14B portfolio in Q2 2020.
- Frazier Management opened 2 new positions and closed 1 in Q2 2020.
- Frazier Management's portfolio value rose 29% quarter-over-quarter to $1.14B.
Based on Frazier Management's 13F filing for Q2 2020, filed 4 Aug 2020.